The intrinsic period of circadian clocks is their defining adaptive property. To identify the biochemical mechanisms whereby casein kinase1 (CK1) determines circadian period in mammals, we created mouse null and tau mutants of Ck1 epsilon. Circadian period lengthened in CK13 À/À , whereas CK13 tau/tau shortened circadian period of behavior in vivo and suprachiasmatic nucleus firing rates in vitro, by accelerating PERIODdependent molecular feedback loops. CK13 tau/tau also accelerated molecular oscillations in peripheral tissues, revealing its global role in circadian pacemaking. CK13
INTRODUCTION
In mammals, daily rhythms of sleep and metabolism are driven by the circadian pacemaker within the suprachiasmatic nuclei of the hypothalamus (SCN) which coordinates the activity of subordinate circadian clocks in other brain regions and in peripheral tissues (Reppert and Weaver, 2002; Hastings et al., 2003; Lowrey and Takahashi, 2004; Saper et al., 2005) . Precise maintenance of circadian period is the defining adaptive property of these clocks. In both brain and periphery, a central concept is that circadian clocks consist of interlocked autoregulatory feedback loops in which CLOCK:BMAL1 heterodimers bind to E box DNA sequences contained within genes encoding the transcriptional repressors PER and CRY. Following their accumulation in the cytoplasm, PER:CRY complexes translocate to the nucleus after a delay of several hours and repress the activity of constitutively bound CLOCK:BMAL1 complexes. These inhibitory complexes are then degraded following a further delay, and the derepression of CLOCK:BMAL1 activity initiates the next circadian cycle of Per and Cry transcription. Mutations in various elements of this core molecular clock have been described, many of which result in either arrhythmia or alteration in period of rest/activity and sleep cycles.
In addition to periodic transcription, posttranslational modifications of clock proteins are crucial for the correct operation of molecular clockworks (Lee et al., 2001; Gallego and Virshup, 2007) . In particular, reversible phosphorylation provides a potential mechanism for the regulated formation of protein complexes, their nuclear entry, and ultimate degradation via ubiquitination pathways, each step of which introduces delays into the feedback loop. Current interest has focused on the role that protein phosphorylation may play in tuning the circadian oscillator to a period of 24 hr. In Drosophila, mutations of CK1 (doubletime, DBT) were the first circadian mutants discovered to involve an enzyme and resulted in either short (dbt s ) or long (dbt l ) rhythms of eclosion and locomotor activity Price et al., 1998) .
The tau mutation of Syrian hamsters was the first mammalian circadian mutation discovered. It causes significant shortening of activity cycles to 20 hr and assorts in a Mendelian fashion (Ralph and Menaker, 1988) . Subsequent mapping studies revealed that this mutation resided within casein kinase 13 as a C to T transversion in position 178 (Lowrey et al., 2000) . Protein expression studies suggested a destabilization of nuclear PER in the tau mutant hamster (Dey et al., 2005) , while recent modeling and biochemical studies suggested that tau is a gain-of-function mutation on specific residues within the PER protein target (Gallego and Virshup, 2007) , likely leading to increased degradation, altered stability, and accelerated protein turnover. It is unknown whether these latter conclusions, developed in cultured cells and mathematical modeling studies, reflect the real circumstances in living animals. Further, it is unclear whether altered degradation of PER involves cellular compartmentalization, whether it is tissue specific (neural versus peripheral), and ultimately how it leads to accelerated molecular timing in the SCN.
To define the role of CK13 in the circadian clockwork, and hence the molecular disturbance underlying advanced sleep phase disorder and accelerated circadian period, we describe here the generation of a mouse model of the hamster tau mutation within CK13 . We adapted the loxP-cre strategy to produce mice carrying the tau allele of the Ck13 gene and used subsequent cre-mediated in vivo disruption of exon 4, which encodes the catalytic domain of CK13 (Lowrey et al., 2000) to generate a Ck13 null allele. This allelic series was assayed by circadian behavioral wheel-running and SCN electrophysiological studies and revealed that tau acts as a gain-of-function mutation, shortening period in a dose-dependent manner. By using PER2 protein reporters (Yoo et al., 2004) , we also define, for the first time, the impact of this mutation on the molecular dynamics of both the SCN and peripheral timers and, within the SCN, highlight the role of accelerated protein turnover in shortening circadian period and activity/rest cycles. Finally, western blotting and imaging studies of both transfected cell lines, primary fibroblasts and SCN tissue derived from CK13 tau mice reveal that CK13 tau specifically targets PERIOD but not CRY proteins during the early nocturnal phase of the circadian cycle, acting on one component of the negative feedback element of the clock, and leading to an acceleration of period by an asymmetric degradation of PER proteins at a specific phase of the circadian cycle.
RESULTS AND DISCUSSION
Generation of a tau Mutant Allele for CK13 and Subsequent Disruption We adapted the loxP-cre recombinase strategy used for creating a conditional knockout to produce a mouse carrying the tau allele of the Ck13 gene. This can be subsequently converted in vivo to a CK13 gene knockout by cre-mediated ablation of exon 4, which encodes the catalytic domain of CK13 (Lowrey et al., 2000 ; see Figure S1A available online). Deletion of exon 4 leads to a frameshift and premature stop codon. The linearized targeting vector was electroporated into ES cells and G418 resistant, homologously recombined ES clones ( Figure S1B ) subjected to transient transfection with cre recombinase followed by FIAU selection. Resistant colonies that had deleted the selection cassette but retained the mutant tau exon were identified by PCR ( Figure S1C ) and used to generate germline transmitting chimeras. The presence of the tau mutation (the C to T transversion at amino acid position 178) in the founder transgenic mice was confirmed by sequencing of animal-derived genomic DNA through the tau site ( Figure S1D ). F1 mice carrying the floxed tau allele were crossed with a deletor cre mouse to generate the Ck13 knockout line. Gene knockout was confirmed genetically by genomic DNA sequencing of the Ck13 gene as well as by RT-PCR using brain cDNA as templates ( Figure S1E ). The absence of the CK13 protein was also confirmed by western blotting in whole-brain extracts using an antibody against the C terminus of CK13 ( Figure S1F ). Mice carrying the tau allele (tau/+ and tau/tau) or the knockout allele (À/+ and À/À) were viable and fertile with no overt deleterious phenotype. ). This is equivalent to 1.80 hr/copy of CK13 tau and virtually identical to the behavioral phenotype of this mutation in Syrian hamsters (6). In contrast, knockout mice exhibited a small but significant period lengthening compared to their WT counterparts (24.0 ± 0.06 versus 23.6 ± 0.05 hr, respectively, p < 0.001; Figures 1A and 1B) . Importantly, mice carrying a single copy of the knockout allele exhibited a WT-like free-running period of 23.7 ± 0.05 hr, while the tau hemizygote (CK13 tau/À , 21.6 ± 0.09 hr) and heterozygote (CK13 tau/+ ) mice exhibited virtually identical periods ( Figures 1A and 1B) . This shows that a single WT copy of Ck13 provides little protective effect in the face of a tau allele and thus offers definitive genetic evidence that tau acts as a gain-of-function mutation.
Interestingly, the absolute number of wheel revolutions per circadian cycle was similar in all genotypes, suggesting period acceleration in the tau mutants may occur due to an asymmetric effect on overall circadian organization, perhaps sparing nocturnal activity per se ( Figures 1C and 1D ). Similar effects are reported for circadian mutations in DBT , the CK1 ortholog in Drosophila. The asymmetric acceleration of circadian timing was extended in studies of metabolic rhythms in the CK13 tau and WT mice using indirect calorimetry. Here, we noted that there was a compression of circadian rhythms of oxygen consumption (VO 2 ) in CK13 tau mice which closely matched the periods determined earlier by wheel running (Figure 2) . Remarkably, the pattern of oxygen consumption was highly asymmetric such that the shortening of period was almost entirely associated with a compression of the inactive (subjective day) phase (active phase duration, WT = 12.6 ± 0.1 hr; CK13 tau = 13.4 ± 0.6 hr; inactive phase duration, WT = 11.4 ± 0.1 hr; CK13 tau = 6.9 ± 0.5 hr; p < 0.01; Figures 2B and 2C ). Hence, our data suggest that the absolute duration of nocturnal physiology and behavior were unaffected by the CK13 tau mutation, rather, nocturnal events were initiated earlier in CK13 tau than in WT. Such observations are compatible with our earlier demonstration in tau mutant hamsters of an advanced onset of circadian nocturnal melatonin secretion, with the result that overall duration of secretion of this nocturnal hormone is identical to that of wild-types (Lucas et al., 1999) . Collectively, these data suggest that CK13 tau may accelerate period by compressing a specific phase of the circadian behavioral and physiological cycle. In the case of the knockout mice, the circadian phenotype was mild (ca 18 min extension in period). Although we have not undertaken measures of oxygen consumption in knockout mice, our analysis of the relative proportion of the circadian cycle in which knockout animals are active (alpha) and the overall structure of the circadian activity cycle revealed that they were not significantly different to wild-types.
Individual Neurons of the SCN Exhibit an Accelerated Firing Rate in CK13 tau Mutants
In order to extend our studies to the SCN, we adopted the use of a suction electrode method which permits discrimination of firing rate profiles for individual cells for over 48 hr in vitro (Brown et al., 2006) . Using acutely prepared SCN slices, we recorded extracellular multiunit electrical activity in animals in which circadian periods had previously been recorded in running wheels in DD, permitting comparison of individual behavioral periods to SCN cellular rhythms. In all genotypes (CK13
À/À ), there was a close concordance with their period of multiunit recording in each slice ( Figure 3A ). SCN single-unit recordings revealed a similar outcome ( Figure 3A) , with a highly significant correlation (r 2 = 0.83, p < 0.01) between rhythms of single unit firing rates and behavior across all four genotypes ( Figure 3B ), indicating that effects of CK13 tau on behavioral (D) Activity levels during the first 4 weeks of DD for each genotype as determined by total wheel-running revolutions per circadian cycle. There were no significant differences between genotypes despite shortened overall circadian period (mean ± SEM).
period likely arose from corresponding changes in circadian patterns of electrical activity of SCN neurons (Brown et al., 2005) . The pattern of electrical activity of the knockout was normal in terms of amplitude and firing frequency, indicating that gene loss did not alter fundamental aspects of SCN electrophysiological properties. Thus, our generation of CK13 tau in mice and subsequent gene deletion has resulted in a novel allelic series of circadian period, ranging from 20.0 (CK13
), and provides an unprecedented resource to explore the central role of CK1 to circadian rhythm regulation in mammals.
Impact of CK13
tau/tau on the Molecular Pacemaker of the SCN and Peripheral Tissues Accelerated circadian periods of activity/rest cycles and also SCN firing rates likely reflect altered dynamics within molecular feedback loops that underpin circadian time-keeping within the SCN. To determine the impact of CK13 on SCN molecular oscillators, CK13 tau mice were crossed into PER2::Luciferase (PER2::LUC) protein fusion reporter mice (Yoo et al., 2004) . Organotypic SCN slices were prepared from 5-to 10-day-old pups and luciferase activity recorded using photomultiplier tubes (PMTs) over a minimum of 7-10 cycles. (B) Representative profiles of VO 2 for Tau and WT normalized to the midpoint (50%) of the trough-to-peak and peak-to-trough amplitudes. Rhythms are double plotted over a 48 hr time base. The ''active'' and ''inactive'' portions of the cycle were defined as the portions of the cycle above or below zero (respectively). (C) Duration of the active (black) and inactive (open) phases of the circadian cycle (mean ± SEM). Duration of active phase was maintained in Tau mice in both LD and LL, when compared with WT mice. In contrast, the inactive (subjective day) portion of the cycle was reduced in Tau mice under both light conditions. As expected, both genotypes exhibited a lengthening of the inactive period when switched from LD to LL. (**p < 0.01 post-hoc Bonferroni). measured using a CCD camera. Single-neuron imaging showed that circadian period of single neurons also matched genotype (24.9 ± 0.09, 22.1 ± 0.04, and 20.5 ± 0.05 hr for CK13 +/+ , CK13
, respectively) and that CK13 tau had no effect on the intercellular synchrony nor regional distribution of circadian gene expression across the SCN ( Figure 4C ). Therefore, these bioluminescence recordings reveal that both the behavioral and electrophysiological impact of the CK13 tau mutation is underpinned by accelerated molecular time-keeping within individual SCN neurons. It is unknown whether endogenous CK13 has a global role in setting clock speed in tissues outside the nervous system. We therefore recorded circadian PER2::LUC activity in organotypic slices of pituitary, lung, and kidney and primary lung fibroblast cultures. This revealed clear circadian expression of PER2 and, on a group basis, a significant shortening of period by CK13 tau (Figures S3A, 4B, and 4D) . In contrast to the SCN, however, the magnitude of effect was variable across tissues, indicating partial penetrance of the mutation. Moreover, in lung and kidney, the tau allele significantly accelerated the rate of damping of the molecular cycle ( Figure S3B ). Thus, our in vitro data show that CK13 tau accelerates pacemaking globally, although its detailed impact on SCN and peripheral oscillators is tissue specific. We hypothesized from our tau mutant hamster studies that CK13 tau may shorten period by accelerating the loss of nuclear PER proteins specifically in the early nocturnal phase (Dey et al., 2005) , leading to earlier derepression of BMAL1 and CLOCK and overall circadian acceleration. This ''asymmetric acceleration'' model of PER protein turnover in CK13 tau mutants was tested in our bioluminescence recordings of SCN slices. By aligning SCN waveforms from WT and CK13 tau ( Figure 4E ) by either peak or nadir of expression, it is evident that the mutation significantly accelerates the decline of PER2::LUC (time to fall to 50% level WT = 5.3 ± 0.3 hr, CK13
tau/tau = 3.9 ± 0.2 hr, ANOVA F = 8.97, p < 0.01). Consequently, the cycle in CK13 tau homozygote slices is advanced by ca 3.4 hr compared to WT over the interval of PER protein decline (hours from peak to trough), whereas over the rising phase CK13
tau/tau has little effect.
Neuron Accelerated Molecular Clockwork in tau Mutant Mice
Additional statistical confirmation of this distorted waveform came from analysis of skewness ( Figure S3C ), slices with shorter periods having a more negative skew due to asymmetric distortion of waveform. Our data show that most of the accelerated degradation of PER within the SCN occurs at a specific phase and that this acceleration is consistent with, and can account for, the period changes observed in wheel-running behavior.
CK13 tau Selectively Accelerates PER Degradation
Independently of Subcellular Localization These data indicate that CK13 tau accelerates the onset of nocturnal processes (but not affecting their absolute duration) by accelerating the clearance of endogenous SCN PER2 proteins predominantly in the early circadian night. To explore the biochemical basis of this effect, we used real-time fluorescence videomicroscopy to monitor PER2::YFP degradation in COS-7 cells following blockade of de novo protein synthesis by treatment with cycloheximide (CHX, 20 mg/ml). Coexpression with WT but not kinase-dead CK13 accelerated PER2::YFP protein degradation, relative to vector control. Degradation was further accelerated by CK13 tau ( Figure 5A ). In contrast, CRY1::CFP degra- dation was not affected by any variants of CK13, indicating a selective action of CK13 on PER2 ( Figure 5B ). Inhibition of nuclear export by leptomycin B (LMB) retained PER2::YFP in the nucleus and slowed its degradation in the presence of WT CK13. In contrast, LMB did not alter the acceleration of PER2 degradation by CK13 tau ( Figure 5C and 5D), confirming a nuclear site of action of this mutation. LMB could alter degradation rates by blocking PER nuclear export or by altering trafficking of other components required for PER degradation. To differentiate between these possibilities, to extend the range of cell types investigated, and to determine the effect of CK13 tau on PER1, we expressed in NIH 3T3 cells WT or mutant forms of PER1 in which either the nuclear export signal was mutated (mtNES) or an additional copy of the nuclear localization signal was added (+NLS). Both mutations trapped most of the PER1 within the nuclear compartment (>65% for mtNES; > 88% for +NLS) as determined by immunocytochemisty ( Figure 5E ). CK13 tau accelerated degradation, not only of wtPER1 as previously reported (Gallego et al., 2006) but also of nuclear-trapped PER1 (residual PER1 at 4 hr post-CHX treatment, CK13 tau versus WT, 45% and 81% for mtNES; 39% and 66% for +NLS; Figure 5F ). In addition, CK13 tau accelerated degradation of another mutant form of PER1 (PER1 1-823 ) which lacked the C terminus that contains an active NLS as well as the CRY binding site (Vielhaber et al., 2001 ) and retained PER1 predominantly in the cytoplasm (>87%; Figures 5E and 5F ). Together, these in vitro data clearly show that CK13 tau targets both PER1 and PER2 but not CRY1 proteins, and this selective targeting occurs regardless of nuclear or cytoplasmic localization.
CK13
tau Also Selectively Accelerates Endogenous PER
Degradation in Primary Cells and SCN Slices
We extended these studies of recombinant protein stability by using western blots to examine native PER1 and CRY1 expression in WT and mutant primary fibroblast cultures. PER1 proteins typically exhibit two clear bands which represent hypo-(lower band) and hyperphosphorylated (upper band) forms of PER1 (Lee et al., 2001 ; Figure 6A ). In tau mutant fibroblasts, the overall levels of PER1 were lower than those seen in WT cells. However, upon treatment with CHX (20 mg/ml), the hyperphosphorylated forms of PER1 displayed a significantly shorter half-life in tau mutant cells than in WT cells (WT, 9.4 hr, versus tau, 4.0 hr, p < 0.05 using nonlinear exponential decay analysis with GraphPad; Figure 6B ). This is consistent with the idea that hyperphosphorylated PER1 may be preferentially targeted to the proteasome for degradation (Gallego and Virshup, 2007) . In contrast, the overall expression level and CHX-stimulated decline of CRY1 was unaffected by CK13 tau (Figures 6A and 6B ). To obtain a more dynamic view of PER degradation, we then exploited real-time recording of primary fibroblasts treated with CHX at the peak of PER2::LUC expression. This revealed that CK13 tau significantly shortened (p < 0.01) the half-life of PER2::LUC expression, by ca. 25 min. Moreover, even though pretreatment with LMB extended the half-life in both genotypes, CK13 tau was still effective at accelerating PER2::LUC degradation (p < 0.01; Figures 6C and 6D ), consistent with the recombinant protein studies of a nuclear action for the mutation. Finally, we tested PER2::LUC degradation in the physiologically relevant context of the SCN slice, again adding CHX at the peak of circadian expression. As with the fibroblasts, loss of PER2::LUC bioluminescence was more rapid in mutant than WT SCN slices ( Figures 6E and 6F ), half-life again being shortened by ca. 25 min. Moreover, the effect of CK13 tau remained following pretreatment with LMB, which had no significant effect on PER2::LUC clearance in either genotype.
Together, these data demonstrate that CK13 tau facilitates the degradation of endogenous PER (but not CRY) proteins in SCN and primary cells, and that blockade of nuclear export does not attenuate the tau phenotype. (E) Waveform alignments by nadir or peak for PER2::LUC rhythms from WT (red) and homozygote (blue) organotypic SCN slices. Data were normalized and then plotted as mean ± SEM (n = 6 per genotype). Note selective reduction in peak to nadir interval regardless of alignment.
Conclusions
In mammals, different forms of CK1 (CK13 and CK1d), act on diverse pathways, including Wnt signaling, neurotransmitter regulation, as well as circadian rhythms. Both CK13 and CK1d complex with PER and CRY (Lee et al., 2001) , while CK1-mediated phosphorylation of BMAL1 increases its transcriptional activity (Eide et al., 2002) . In humans, circadian familial advanced sleep disorders (FASPS) are known to be caused by a serine to glycine substitution in the hPer2 gene at position 662 (Toh et al., 2001 ) and also by a T44A missense mutation in human Ck1d, which causes hypophosphorylation of PER2 (Xu et al., 2005) . Transgenic mice overexpressing the hPER2 mutation exhibit shorter free-running periods, mimicking FASPS (Xu et al., 2007) , and their phenotype is sensitive to CK1d: increased dosage of CK1d shortens their period further. These studies, together with recent in vitro analyses of the equivalent serine residue on mouse PER2 protein (Vanselow et al., 2006) suggest that expression, degradation, nuclear entry and export of PER2 are modulated by multiple states of phosphorylation and that CK1 activity plays a central role at these various checkpoints of the circadian cycle (Gallego and Virshup, 2007; Mignot and Takahashi, 2007) .
By creating null and tau mutations of CK13 in mice, we provide behavioral, neurophysiological, and cellular evidence showing that CK13 tau acts as a gain of function that accelerates the molecular dynamics of circadian time-keeping. These biochemical actions explain the behavioral and physiological phenotype of the mutation in both hamsters and mice. They also provide a new perspective with which to understand the action of PER2 and CK1 mutations which have been linked to circadian period and sleep disturbances in humans (Xu et al., 2005 (Xu et al., , 2007 . Our data therefore confirm and extend the earlier modeling-based studies, later tested in cell-line studies (Gallego et al., 2006) . Moreover, we show that this acceleration is a consequence of enhanced rates of degradation of PER proteins at specific phases of the circadian cycle i.e., early circadian night, and that such asymmetric effects on PER degradation are translated into altered phasing of physiological and behavioral circuits. Our studies also reveal that CK13 tau can act on both nuclear and cytoplasmic targets but suggest that within the SCN, CK1-mediated degradation may be primarily a nuclear event, as predicted by our studies of the hamster mutant (Dey et al., 2005) . We also show that the knockout of Ck13 has a relatively mild phenotype (extends the circadian period by ca 18 min a day) and that a single wild-type allele offer no significant protection in the presence of the tau allele. A clear implication therefore is that CK1d may phosphorylate target PERIOD proteins and that wild-type CK13 may thus be partially redundant in the circadian timing mechanisms. Resolution of these issues awaits characterization of the phenotypes of Ck1d knockouts.
An intriguing feature of our data is that the duration of molecular night is relatively compressed due to the accelerated clearance of PER2 after its peak expression at CT12, but the duration of nocturnal behavioral and physiological processes (CBT, melatonin secretion) is apparently normal, as measured in solar time. Consequently, because the offsets are not governed by the molecular cycle, they occur several hours later than the compressed molecular cycle would predict: nocturnal processes spilling over into the start of the molecular day. Hence the behavioral day (defined by activity offset and onset) is shorter in the mutant, even though the underlying determining change is shortening of the molecular night. These strongly asymmetric effects of CK13 tau on molecular and behavioral timing likely underlie the pronounced disturbances of circadian timekeeping (damped amplitude, altered phasing) widely observed in the peripheral tissues of tau mutant hamsters (Dey et al., 2005) and may contribute to poor growth and general morbidity associated with the mutation in hamsters (Lucas et al., 2000) . The variable responses of peripheral tissues to the tau mutation are intriguing and may suggest tissue-specific differences in the relative expression of CK13 or CK1d, or cellular differences in the manner in which PERIOD proteins are trafficked and degraded.
Endogenous PER (but not CRY) proteins (PER1 by western blot, PER2 by bioluminescence recording) are destabilized in the tau mutant background. These effects on protein half-life occur in a context (treatment with cycloheximide) where transcription is irrelevant and thus the observed protein instability is sufficient to explain the behavioral phenotype in full. This point is reinforced by our original findings in the tau mutant hamster (Dey et al., 2005) which showed that the Per mRNA cycle in the SCN mapped to circadian time whereas the PER protein expression cycle was accelerated in vivo due to early clearance. These results from the kinase mutants therefore provide a valuable counterpoint to those of Xu et al. (2007) , who modeled human FASPS by creating mice carrying transgenes encoding mutated versions of the human PER2 protein. The S662G mutation in hPer2, which leads to one form of FASPS in patients, shortened circadian period but the apparent degradation rate of PER2 protein was unaltered. Rather, expression of hPer2 mRNA was reduced, leading to lower hPER2 protein levels. Our findings with the kinase mutant therefore add further support to the speculation of Xu et al. (2007) that effects mediated via S662 may accelerate the clock by reduced transcription, whereas the tau mutation, as a gain-of-function of CK13, targets a separate domain within PER2 which is responsible for accelerated degradation.
The lack of impact of CK13 tau on CRY dynamics complements the recent description of loss-of-function mutations on F box proteins, which mediate actions on CRY degradation, resulting in a longer half-life of CRY proteins Busino et al., 2007; Siepka et al., 2007) . As a result, circadian period is lengthened. These studies and data reported here further suggest that mechanisms for the degradation of these two core circadian transcription factor families (PER and CRY) operate independently but must have tightly coevolved in order to achieve precise overall control on circadian period. Our new mouse model therefore provides new insight into how a circadian mutation accelerates behavioral and cellular circadian rhythms, in both the brain and peripheral tissues, and demonstrates that temporally specific effects on PER degradation can be tracked through to an altered circadian structure of behavior and physiology.
EXPERIMENTAL PROCEDURES Animal Maintenance
All experiments were conducted under the aegis of the 1986 Home Office Animal Procedures Act (UK) and following local ethical review. All animals were reared at 20 C-22 C and maintained on standard rodent breeder or maintenance chow under 12 hr light:12 hr dark lighting schedules.
Antibodies and Plasmids
Monoclonal anti-CK13 antibody was obtained from BD Transduction Laboratories, and anti-Myc (9E10) antibody from Santa Cruz Biotechnology. Anti-PER1 and Anti-CRY1 antibodies were a kind gift from Choogon Lee. Polyclonal anti-Myc antibody (9106) was from ABCAM and anti-a-Tubulin (T6199) and anti-actin (A2066) from Sigma. Myc-PER1 constructs were cloned in PCS2+MT vector and HA-tagged kinases (CK13 WT and tau mutant) were cloned in pCEP4 (Invitrogen). The SV40 Tag NLS (PKKKRKVG) was added to the 5 0 end of Myc-mPER1 by PCR (Gallego et al., 2006) . Full-length mPer2 cDNA with C-terminal enhanced yellow fluorescent protein tag derived from pEYFP-N1 (Clontech) was cloned into pcDNA3.1/V5/HisA vector (Invitrogen) (PER2::YFP). Full-length mCry1 cDNA was cloned into enhanced cyan fluorescent protein vector pECFP-N1 (Clontech) (CRY1::CFP). Tau mutation plasmid for transfection was prepared by site directed mutagenesis leading to a substitution of arginine 178 (*C*GC) by cysteine (*T*GC). Kinase-dead variant was prepared by substitution of lysine at position 38 (AAG) by alanine (GCC). Ck13 plasmid was generously donated by Achim Kramer (Humboldtuniversity, Berlin, Germany). Wild-type, tau, or kinase-dead variants of full-length Ck13 cDNA were cloned into pcDNA-DEST40 vector (Invitrogen) (WT, Tau, KD).
Generation of Transgenic Mice
The targeting construct contained exons 2-6 of the Ck13 gene ( Figure S1 ) was prepared using sv129 genomic DNA fragments from a PAC clone. Briefly, an 8.7 kb SalI-XbaI fragment encompassing exons 2-6 was subcloned into pBluescript (KS+) and verified by end-sequencing. The 1.4 kb BglII-EcoRI fragment containing exon 4 was used to introduce the tau mutation (C12555T) by site-directed mutagenesis and verified by sequencing. A floxed NeoTK selection cassette was inserted into the EcoRI site in the intron 4, and a double stranded oligo encoding lox P and NcoI sites ligated into the BglII site 5 0 of exon 4 ( Figure S1A ). The targeting construct was linearized with NotI, electroporated into 129/Sv R1 ES cells (http://www.mshri.on.ca/nagy/r1.htm), and genomic DNA from G418-resistant clones isolated as described previously (Talts et al., 1999) . BglII-digested DNA was Southern blotted and hybridized with 32 P-labeled external probe, amplified from genomic DNA using the following primers: forward 5 0 -ACTTCCTTCTCTTTACCCACG-3 0 ; reverse 5 0 -AGAAG CAAGCATCCATTTCC-3 0 . The floxed selection cassette was deleted from homologously recombined ES cell clones by transient transfection with a cre-expressing plasmid followed, 48 hr later, by 5 days of FIAU (1-(2-deoxy-2-fluoro-b-D-arabino-furanosil)-5-iodouracil) selection (Abuin and Bradley, 1996) . FIAU-resistant colonies were expanded and genomic DNA analyzed by PCR as described below to determine whether they were tau or knockout alleles. ES cell clones carrying the tau allele (tau/+) were used to create germline-transmitting chimeras by blastocyst injection. tau/+ mice were crossed with littermates to produce homozygous tau offspring allele or crossed with a deletor cre line to generate the Ck13 knockout allele in vivo. Wild-type (+) and tau alleles were genotyped by PCR using primers ''a'' (5 0 -CACCTGGGC ATTGGTGAGT-3 0 ) and ''b'' (5 0 -GGAGGTCAAGGGGCCAGT-3 0 ) ( Figure S1A ).
The presence of the knockout (À) allele was detected using primers ''c'' (5 0 -GTGGTAGAAGGAGAGAACTGAC-3 0 ) and ''b'' (see above). In all, 11 chimeric mice derived from 3 clones were used to generate a founder line of Ck13 mice, which were then introgressed over six generations into a C57/B6 background.
RT-PCR
Total RNA from brain of CK13 knockout mice and wild-type siblings was isolated using Trizol (Invitrogen). To exclude genomic DNA contamination, total RNA was digested with DNase I (Roche). One microgram of total RNA was reverse transcribed using Oligo-dT oligonucleotides by the SuperScript II RNase H-Reverse Transcription kit (Invitrogen). In parallel, negative control samples lacked Reverse Transcriptase. Two microliters of the resultant first strand cDNA was PCR amplified with appropriate primer pairs using a hot-master PCR kit (Eppendorf) as follows: (1) Western Blotting of CK13 Protein extracts were prepared from whole brain of wild-type, CK13 knockout, and CK13 tau/tau mice. Mice were euthanized by cervical dislocation; whole brains were removed and frozen on dry ice. Tissues were mechanically homogenized at 4 C in three volumes of extraction buffer (0.1 M KCl, 20 mM HEPES [pH 7.5], 5 mM EDTA, 1 mM dithiothreitol, 0.1% Triton X-100, 5% glycerol, 0.5 mM phenylmethylsulfonyl fluoride [PMSF], 1 mM MgCl 2 , 10 mg/ml of aprotinin, 5 mg/ml of leupeptin, 1 mg/ml of pepstatin A). Homogenates were cleared by centrifugation (23 10 min, 13,000 3 g at 4 C). Supernatants were mixed with 23 protein loading buffer, boiled, and spun at 13,000 3 g for 1 min at room temperature. Total protein (70 mg) was resolved on 10% denaturing PAGE gels and transferred to nitrocellulose membrane (Bio-Rad). Membranes were blocked with 5% skimmed milk in Tris-buffered saline containing 0.05% Tween 20 and incubated with relevant antibodies. ECL plus detection was used (Amersham Biosciences).
Behavioral Analysis
Six-to sixteen-week-old mice were single-housed in cages equipped with running wheels and ad libitum food and water, contained within a light-tight chamber at constant temperature ( C) and humidity (% H 2 O). Mice were entrained to a 12hr light and 12 hr dark (LD) cycle for 7 days and released into constant darkness (DD) for $28 days. Wheel revolutions were recorded in 10 min time bins by DataQuest III acquisition program (Data Sciences Inc.), transferred to the TauActo 1.2 analysis software (developed in house by T. Brown) to produce double-plotted actograms, periodogram, intensity of running(alpha/rho), and power of rhythm. c 2 periodogram analyses were performed using 28 days of data in DD.
Electrophysiological Recordings
Electrophysiological recordings were conducted and analyzed as previously described (Brown et al., 2006) . Mice (housed with running wheels in DD) were killed at the beginning of the inactive phase, and coronal brain sections (350 mm thick) were cut using a vibroslicer (Campden Instruments) and transferred to an interface style brain slice chamber continuously perfused ($1.5 ml/min) with oxygenated (95% O 2 /5% CO 2 ) aCSF supplemented with 0.0005% gentamicin (Sigma) and warmed to 36 C ± 1 C. Extracellular multiunit activity (MUA, signal-to-noise > 2:1) was recorded from the SCN using aCSF-filled suction electrodes, differentially amplified (320,000) and bandpass filtered (300-3000 Hz) via a Neurolog system (Digitimer), digitized (25,000 Hz) using a micro 1401 mkII interface (Cambridge Electronic Design [CED]), and recorded on a PC running Spike2 version 5 software (CED).
Single-unit activity was discriminated from MUA recordings offline on the basis of waveform shape and validated by measurement-based clustering and the presence of a clear refractory period in an interspike interval histogram. Firing rate data were moderately smoothed using a 1 hr moving average and presented as the mean firing rate each min. The circadian period of single-cell and MUA rhythms were analyzed by curve-fitting developed in-house (Clockwise; Dr. T. Brown). Initially, data were normalized such that data spanned a range of values between 100 and À100. The normalized data were then fit with the equation Y = Asin(B(x+C)) using the Newton-Raphson iterative method, where A equaled the amplitude of the rhythm, B equaled the period in radians/hr and C determined the phase. Initial values of A, B, and C were estimated from the best fitting curve of a series of >3000 standard curves that spanned the period range 3-34 hr and exhibited a range of different amplitudes and phasing. Peak widths were defined as the duration over which firing rate was above the mean for that cell.
Metabolic Rhythm Measurement and Analysis

Indirect Calorimetry
Tau and WT mice (n = 6 per genotype) were single-housed in indirect calorimetric cages (Columbus Instruments). Mice were monitored for a minimum of 10 days in LD followed by a minimum of 5 days in constant light (LL), during which time oxygen consumption (VO 2 ) was measured every 10 min. Illustrations of VO 2 traces in Figure 2 depict group (genotype) averages taken from a representative experiment.
Analysis of Metabolic Rhythms
Circadian rhythms in VO 2 were analyzed using curve-fitting software (Clockwise) as described above. Recordings from individual animals during LD and LL portions of the experiment were analyzed separately. Once period length was determined, a composite circadian cycle of metabolic rate was generated for each animal from the entire test period (a separate composite was generated for each lighting condition). From these representative circadian profiles, ''active'' and ''inactive'' portions of the cycle were determined by normalizing metabolic rate to the midpoint (50%) of the peak to trough amplitude, calculated separately for the rise and fall of the rhythm. Duration of active and inactive phases in LD and LL was analyzed using repeated-measures two-way ANOVA, with a Bonferonni's post hoc test.
Bioluminescence Recording and Imaging
Whole-slice bioluminescence emission and individual cellular emission were recorded as described (Maywood et al., 2006; Prosser et al., 2007) using photomultiplier assemblies and CCD cameras supplied by Hamamatsu. Waveforms of rhythmic bioluminescence emission from whole slices and individual cells were analyzed in BRASS software and RAP algorithm.
Cell Isolation, Culture, and Transfection For culture of primary lung fibroblast, lungs were removed from euthanized adult mice for peripheral fibroblast preparation. Briefly, lung was chopped and minced in sterile conditions and washed twice in chilled modified Hank's Balanced Salt Solution (Sigma). Cells were then dissociated by means of shaking at 37 C for 2 hr in 100 u/ml of Collagenase IA (Sigma) (dissolved in PBS) and 3 mM CaCl 2 . Once dissociated, cells were filtered through a sterile nylon mesh followed by two washes and centrifugation in chilled Hank's solution. Pellets were resuspended in culture medium (DMEM with 4.5 g/l glucose, Glutamax, and pyruvate, supplemented with 10% FBS, 100 U/ml Penicillin, and 100 mg/ml streptomycin) and plated on a 10 cm culture dish. Cultures were maintained at 37 C (5% CO 2 ) for 2-3 days until confluent and ready for splitting. Confluent cells in 35 mm dishes were synchronized with Dexamethasone (100 nM) for 1 hr prior to PMT recording of PER2::LUC bioluminescence (Izumo et al., 2003) . NIH 3T3 cells were grown in DMEM supplemented with 10% calf serum and antibiotics. At 90% confluence in 6-well plates, cells were transfected with relevant plasmid combinations using Lipofectamine 2000 (Invitrogen). The amount of transfected DNA was 0.8 mg of Myc-Per1 and 0.4 mg encoding HA-tagged kinases for each well. COS-7 cells were grown in DMEM supplemented with 10% calf serum and antibiotics. At 80%-90% confluence in glass-bottomed dishes (MatTek), cells were transfected with combinations of relevant plasmids using 3 ml of GeneJuice (Novagen). The total amount of transfected DNA was 1 mg (0.6 mg of Per2::YFP + 0.4 mg of CK1 3 or 0.5 mg of Cry1::CFP + 0.5 mg of CK13) for each dish. Twenty-four hours after transfection, DMEM was exchanged for air medium and subjected to live cell fluorescent imaging (Maywood et al., 2006) .
Protein Degradation Assay
For real-time monitoring of PER2::YFP and CRY1::CFP degradation, COS-7 cells were treated with 20 mg/ml cycloheximide (Sigma), with or without LMB pretreatment (10 ng/ml for 1 hr; Calbiochem). Fluorescence was recorded every 15 min for at least 17 hr by time-lapse microscopy using Openlab software (Improvision, Warwick, UK). Single cell fluorescent data were analyzed by IPlab software (Scanalytics, B.D. Bioscience, Rockville, MD) and onephase exponential decay curve fitting. Half-life calculations and statistics were performed in Prism (GraphPad Software). Data were plotted as mean ± SEM with fitted exponential decay curve. Half-lives are plotted as mean ± 95% confidence interval of exponential decay curve fitting.
For detection of Myc-tagged PER1 degradation by western blotting, 20 hr after transfection, cells were treated with CHX (40 mg/ml) for 0, 2, and 4 hr and then lysed in lysis buffer (150 mM NaCl/20 mM HEPES [pH 7.5]/0.1% Nonidet P-40/1 mM EDTA/2 mM DTT) supplemented with 13 Complete protease inhibitor mixture (Roche Applied Science). The cells were then mechanically sheared, and lysates were centrifuged at 16,000 3 g for 10 min at 4 C. Total protein (100 mg) was resolved in SDS/PAGE and then subject to western blotting. For endogenous PER1 and CRY1 degradation, primary lung fibroblasts were treated with CHX (20 mg/ml) for 0, 1, 2, 4, and 6 hr then subjected to western blotting using anti-PER1 and anti-CRY1 antibodies. These experiments were duplicated. For real-time monitoring of PER2::LUC degradation by PMT, SCN slices or lung fibroblasts were treated with CHX (40 mg/ml) with or without LMB pretreatment (10 ng/ml for 1 hr). For control experiments, DMSO (for CHX) or ethanol (for LMB) was used as vehicle.
Immunostaining of PER1 and Mutants in NIH 3T3 Cells Twenty hours after transfection of different PER1 constructs, cells were replated on glass coverslips. Twenty-four hours later, cells were washed three times with phosphate-buffered saline (PBS) and fixed with 3.7% paraformaldehyde for 15 min. After three more washes, cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min and washed with 3% BSA/0.1% TX-100/PBS for 30 min. Cells were incubated with an anti-Myc polyclonal antibody for 1 hr in 3% BSA/0.1% TX-100/PBS, washed three times, and incubated with a secondary Alexa Fluor 594 goat anti-rabbit IgG (Molecular Probes, Inc.) for 1 hr. Cells were washed three and incubated with DAPI (1 mg/ml) in 0.1% TX-100/PBS. Cells were visualized using an Olympus AX70 fluorescence microscope (magnification 3 60), and images were digitally recorded via an AxioCam (Carl Zeiss MicroImaging, Inc.) and saved using the AxioVision 3.1 program. Overlays of the immunofluorescence images were performed in Photoshop (Adobe).
SUPPLEMENTAL DATA
The Supplemental Data for this article can be found online at http://www. neuron.org/cgi/content/full/58/1/78/DC1/.
